



AD-HOC-ANNOUNCEMENT ACCORDING TO §15 WPHG

PRODUCTS

PAION AG: RECRUITMENT FOR PHASE III STROKE STUDY DIAS-2 ON HOLD

Aachen (Germany), 25 October 2006 - Biopharmaceutical company PAION AG today announced that the Steering Committee of the Phase III study DIAS-2 with PAION's drug candidate Desmoteplase has decided in agreement with Forest Laboratories, Inc. and PAION to set patient recruitment temporarily on hold until further data have been analysed.

The Steering Committee followed a recommendation by the Data Monitoring Committee (DMC). The DMC had requested additional safety relevant data in order to facilitate the evaluation of a potential safety signal, which was not specified further by the DMC. The DMC had notified in its statement that no conclusion on safety or efficacy of Desmoteplase should be drawn from this recommendation. The requested data have been processed and will be provided to the DMC within the next day.

Contact

Dr. Peer Nils Schroeder, Investor Relations / Public Relations
PAION AG

Martinstrasse 10-12

52062 Aachen – Germany

Tel. +49 (0)241 4453 152

Email pn.schroeder@paion.de

www.paion.de